– DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell Lung Cancer Cell Lines and Decrease Tumor Burden in Combination with Osimertinib and ...
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback